Age 24 is a time of energy and endless possibilities for a young woman. It is also the average age of diagnosis for small cell carcinoma of the ovaries hypercalcemic type (SCCOHT) - a highly aggressive tumor that kills more than 65 percent of patients within two years of initial diagnosis.
In 2014, the Translational Genomics Research Institute (TGen) led an international team of scientists and clinicians to find the genetic basis of this ovarian cancer. Until then, little was known of the biological underpinnings of this deadly disease.
As a result of this study, TGen has identified treatments that have shown astonishing results in preventing these ovarian tumors from growing in lab models, and we are ready to bring these therapies to a clinical trial.
In addition to making a difference for ovarian cancer patients, we are finding evidence that the therapies tested might be able to treat a broader range of cancers including pancreas, lung, head and neck, colorectal, as well as a broader set of ovarian cancer types.
Today, we have an amazing opportunity to build on our previous success against this disease, and to keep momentum moving forward towards a cure. Today, we ask you to join our fight against ovarian cancer by supporting TGen’s Small Cell Ovarian Cancer Clinical Trial.
